Direkt zum Inhalt
Merck

Topical nicotinamide for seborrheic dermatitis: an open randomized study.

The Journal of dermatological treatment (2013-06-15)
Gabriella Fabbrocini, Mariateresa Cantelli, Giuseppe Monfrecola
ZUSAMMENFASSUNG

Treatment of seborrheic dermatitis (SD) includes various options with different success and safety limitations. To evaluate the efficacy of topical nicotinamide (NCT) in the treatment of SD. A total of 48 patients with mild to moderate SD of the face were enrolled in the study (36 males and 12 females; age 20-50 years). Patients were randomized into two groups A and B, who were treated once a day with topical administration of NCT 4% cream and with the vehicle without NCT (placebo), respectively. Clinical measures were assessed by erythema, scaling, and infiltration, which were evaluated using a four-point scale 0-3 before starting treatment and after 2, 6, and 12 weeks' therapy. In comparison with baseline, a reduction of 75% of the total score was observed in patients treated with NCT, whereas for placebo-treated patients the reduction was of 35% (p < 0.05). Topical NCT 4% can have a potential for the treatment of SD.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Nicotinamid, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Nicotinamid, ≥99.5% (HPLC)
Supelco
Niacinamid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Nicotinamid, ≥98% (HPLC), powder
USP
Niacinamid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Niacinamid, meets USP testing specifications
Supelco
Nicotinamid (Vitamin B3) -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Nicotinamid, ≥98.5% (HPLC)
Nicotinamid, European Pharmacopoeia (EP) Reference Standard